AngioScore Inc.

www.angioscore.com

High-Tech Company

Acquired by Spectranetics

TECH VERTICALS

Healthtech, Life Sciences, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	Revenue Growth
Established	2003
Number of Employees	30

DESCRIPTION

AngioScore is a developer of novel angioplasty catheters for use in the treatment of coronary and peripheral artery disease. The company’s flagship product, the AngioSculpt(R) Scoring Balloon Catheter, incorporates a unique system of nitinol scoring elements with a traditional balloon catheter. The scoring elements create focal concentrations of dilating force, which minimize balloon slippage (geographic miss) and assists in the luminal expansion of stenotic arteries.

TECHNOLOGY

Angioplasty - The AngioSculpt Scoring Balloon Catheter is a line of innovative coronary angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.

The AngioSculpt Scoring Balloon Catheter is intended for the treatment of a hemodynamically significant coronary artery stenosis, including in-stent restenosis, for the purpose of improving myocardial perfusion. The AngioSculpt catheter was developed to address the clinical need for a safe, high performance “workhorse” predilatation catheter that also provides the benefits of plaque scoring in complex cases such as calcified lesions, small vessels and in-stent restenosis. Treatment of these complex lesions can be complicated by challenging anatomy that makes catheter delivery difficult, balloon slippage leading to “geographic miss”, elastic recoil and the need to use high pressures. Combining deliverability comparable to that of high performance angioplasty balloon catheters with the benefits of plaque-scoring and a high rated burst pressure (up to 20 atm), the AngioSculpt catheter is the catheter of choice for complex lesions.

Products and Phases

Product	Phase
AngioSculpt	FDA Approved
Scoring balloon catheter for coronary and peripheral applications

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Cardiologists

CONTACT INFO

Expand / Collapse All

Main Address: Fremont, United States

Address	5055 Brandin Court
City	Fremont
State/Province	CA
Country	United States
Zip	94538

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Thomas Trotter	President & CEO
Dr. Gary Gershony	Chief Medical Officer & Co-Founder
Mr. James Andrews	SVP & CFO
Mr. Richard P. Cassidy	SVP, Global Sales and Marketing
Mr. Kent Jones	SVP, Regulatory and Quality
Mr. Samuel Omaleki	SVP, Operations
Mr. Peter Johansson	VP, R&D
Mr. Tanhum Feld	Co-Founder	Advanced Stent Technologies (Director of R&D)
Mr. Ephraim Heller	Co-Founder	AngioScore (CEO & Co-Founder)
Dr. Eitan Konstantino	Co-Founder	Advanced Stent Technologies (CEO)
Dr. Nimrod Tzori	Co-Founder	Advanced Stent Technologies (CTO)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Chairman , Elliott Investment Company
abC Defghij	Board Member	VP, CFO , Aspect Medical Systems
abC Defghij	Board Member	Co-Founder & Partner , Telegraph Hill Partners
abC Defghij	Board Member	Founder & Partner , QuestMark Partners
abC Defghij	Board Member	CEO, AngioScore
abC Defghij	Board Member	Principal , Telegraph Hill Partners
abC Defghij	Board Member	Managing Director , Saints VC
abC Defghij	Board Member	Co-Founder, AngioScore

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

May. 28, 2014

Revenue Growth

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Sixth Round

Apr. 27, 2011

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Secondary Fund	abCDe	Led the round
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe

Venture Lending

Oct. 01, 2010

Initial Revenues

abCDe

Fifth Round

Oct. 10, 2007

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe

Fourth Round

Apr. 13, 2006

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Other	abCDe	Led the round
abC Defghij	Other	abCDe

Third Round

Aug. 26, 2005

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe

Second Round

Aug. 23, 2004

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	Other	abCDe

First Round

Jun. 01, 2003

R&D

abCDe

Last Updated:	abCDe
IVC Number:	abCDe